Les coûts élevés des nouveaux médicaments contre le diabète découragent-ils les patients éligibles ?
Nouvelles du monde,
Moins de 10 % des patients américains éligibles atteints de diabète de type 2 ont utilisé un agoniste des récepteurs du GLP-1…
Moins de 10 % des patients américains éligibles atteints de diabète de type 2 ont utilisé un agoniste des récepteurs du GLP-1…
Based on nationally representative data, less than 10% of eligible US patients with type 2 diabetes are on GLP-1 receptor…
Endocrinology > Type 2 Diabetes Data show most eligible patients are not using GLP-1 receptor agonists or SGLT2 inhibitors by…
When I heard that my patient was back in the ICU, my heart sank. But I wasn’t surprised.
When I heard that my patient was back in the ICU, my heart sank. But I wasn’t surprised.
When I heard that my patient was back in the ICU, my heart sank. But I wasn’t surprised.
When I heard that my patient was back in the ICU, my heart sank. But I wasn’t surprised.
When I heard that my patient was back in the ICU, my heart sank. But I wasn’t surprised.
- NewsBreak When I heard that my patient was back in the ICU, my heart sank. But I wasn’t surprised.
Study Design: Retrospective cohort study with multiple pretests and posttests. Methods: Included patients initiated second-line…